From A to X: Next-Gen Targets & Interventions for Alloimmunity, GVHD, and Xenotransplantation

Moderator(s)

• 

  Jaebok Choi, PhD, MA (he/him/his)

  Assistant Professor
  Washington University School of Medicine, St. Louis, MO, United States
• GC

  Geoffrey Camirand

  University of Pittsburgh

Presentations:

• 3:45 PM - 4:00 PM US ET

  PKN1 is a Novel Therapeutic Target for the Optimal Control of GvHD
  

  Author: Jaebok Choi, PhD, MA (he/him/his) – Washington University School of Medicine, St. Louis, MO
• 4:00 PM - 4:15 PM US ET

  IL-39/IL-39R Signaling Drives Acute Graft-versus-Host Disease by Promoting Pathogenic T-Cell Responses
  

  Author: Denggang Fu, DF (he/him/his) – Medical College of Wisconsin
• 4:15 PM - 4:30 PM US ET

  Evidence for Human Thymopoiesis in a Porcine Thymus Graft and T Cell Tolerance to the Source Pig in a Human Recipient of a Thymokidney Xenotransplant
  

  Author: Farshid Fathi, PhD (he/him/his) – Columbia University
• 4:30 PM - 4:45 PM US ET

  Coordinated circulating and tissue-based T cell responses precede xenograft rejection
  

  Author: Ekaterina Novikova, MD – New York University Grossman School of Medicine
• 4:45 PM - 5:00 PM US ET

  Tim-4 Effector B Cells Express a Th17-Like Proinflammatory Cytokine Module That Is Restrained by Nur77
  

  Author: David Rothstein, MD (he/him/his) – University of Pittsburgh
• 5:00 PM - 5:15 PM US ET

  Metabolic Regulation of Alloimmunity: Inhibition of PKM2 Attenuates T Cell Activation and Prolongs Allograft Survival
  

  Author: Daniel Marconi Mendes, PhD (he/him/his) – Massachusetts General Hospital